Skip to main content

Table 2 Prevalence (n (%)) of COPD and CAO by age groups, sex, area and among all subjects

From: Decreased COPD prevalence in Sweden after decades of decrease in smoking

  Age groups Sex Area All
 < 40 years 41–60 years  > 60 years
Women Men Women Men Women Men Women Men Western Sweden Northern Sweden
n = 257 n = 202 n = 438 n = 356 n = 273 n = 313 n = 968 n = 871 n = 1148 n = 691 n = 1839
CAO: FEV1/FVC < 0.7 5 (1.9) 8 (4.0) 23 (5.3) 26 (7.3) 45 (16.5) 53 (16.9) 73 (7.5) 87 (10.0) 93 (8.4) 64 (9.3) 160 (8.7)
CAO: FEV1/FVC < 0.7 & FEV1 < 80% 1 (0.4) 1 (0.5) 6 (1.4) 15 (4.2) 23 (8.4) 26 (8.3) 30 (3.1) 42 (4.8) 42 (3.7) 30 (4.3) 72 (3.9)
COPD: FEV1/FVC < 0.7 4 (1.6) 6 (3.0) 18 (4.1) 25 (7.0) 34 (12.5) 41 (13.1) 56 (5.8) 73 (8.3) 74 (6.4) 54 (7.8) 128 (7.0)
COPD: FEV1/FVC < 0.7 & FEV1 < 80% 1 (0.4) 1 (0.5) 5 (1.1) 15 (4.2) 19 (7.0) 24 (7.7) 25 (2.6) 40 (4.6) 38 (3.3) 27 (3.9) 65 (3.5)
  1. CAO Post-bronchodilator chronic airway obstruction, COPD CAO in combination with respiratory symptoms
  2. Prevalence is reported as n (%). COPD: FEV1/FVC < 0.7 & FEV1 < 80% of predicted corresponds to moderate to severe COPD, i.e. GOLD stage ≥ 2
\